Evidence mapPaperPMID 41555286Full record

ArticleBMC psychiatry2026

Suicide risk in prostate cancer patients: epidemiological trends and a predictive modeling.

Yu-Xuan Yang, Gui-Chen Ye, Qing-Xu Yao, Xing-Yu Zhong, Yi-Fan Xiong, Ming-Liang Zhong, Xi Gong, Shao-Gang Wang, Qi-Dong Xia

Abstract read
In one paragraph

Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yu-Xuan Yang *Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China.
Gui-Chen Ye *Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China.
Qing-Xu Yao *Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China.
Xing-Yu ZhongDepartment and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China.
Yi-Fan XiongDepartment and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China.
Ming-Liang ZhongDepartment and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China.
Xi GongDepartment and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China.
Shao-Gang Wang *Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China. sgwangtjm@163.com.
Qi-Dong Xia *Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan, 430030, P. R. China. qidongxia_md@163.com.

Funding

Hubei Urology Minimally Invasive Therapy Clinical Medical Center SCZ2023015Natural Science Foundation of Hubei Province ZRMS2020002466
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is a common malignancy among men. Although survival rates have steadily improved, some patients still face an increased risk of suicide following diagnosis. Understanding the temporal patterns and key risk factors associated with suicide after a PCa diagnosis is crucial for developing effective intervention strategies. However, comprehensive models for individualized suicide risk prediction remain limited.

methodsThis study utilized data from the SEER database covering the period from 2010 to 2021. First, the suicide mortality trend among PCa patients was assessed by calculating the standardized mortality ratio (SMR). Subsequently, variable selection was performed using the least absolute shrinkage and selection operator (LASSO) regression, combined with Cox proportional hazards regression to further identify independent risk factors associated with suicide risk. A total of 404,120 eligible patients were included for model construction and randomly divided into training and validation cohorts at a 7:3 ratio. Based on the results of multivariable Cox regression, a nomogram prediction model was developed. The model’s performance was evaluated and validated using the concordance index (C-index), receiver operating characteristic (ROC) curves, and calibration curves.

resultAmong 475,139 PCa patients identified, the suicide risk was highest during the first six months after diagnosis (SMR = 26.007, 95% CI: 19.303–34.287) and declined significantly after five years. Nine independent risk factors, including age, race, and Gleason score, were incorporated into the nomogram model. The model showed strong predictive performance, with C-indices of 0.714 and 0.685 in the training and validation cohorts, respectively. ROC curve analysis demonstrated good discrimination ability, and calibration curves indicated excellent agreement between predicted and observed outcomes.

conclusionThis study highlights the heightened risk of suicide among PCa patients, particularly within the first six months following diagnosis, underscoring the urgent need for early psychological intervention. The developed nomogram provides an effective tool for personalized suicide risk assessment, enabling clinicians to identify high-risk patients and implement targeted preventive strategies. Integrating mental health care into routine oncology practice may significantly improve overall patient outcomes. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Prostatic NeoplasmsSuicideAgedHumansMaleMiddle AgedNomogramsProportional Hazards ModelsRisk AssessmentRisk FactorsSEER ProgramNomogramPrognosisProstate cancerSuicide

Identifiers

PMID41555286
PMCPMC12903677

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.